COVID-19 and Indian population: a comparative genetic analysis

Saurabh Patil, Sandhya Kiran Pemmasani, Neelima Chitturi, Ishita Bhatnagar, Anuradha Acharya, Lingareddy Venkata Subash
doi: https://doi.org/10.1101/2021.12.15.21267816

ABSTRACT

Background Major risk factors of COVID-19 include older age, male gender, and comorbidities. In addition, host genetic makeup is also known to play a major role in COVID-19 susceptibility and severity. To assess the genetic predisposition of the Indian population to COVID-19, a comparative analysis of the frequencies of polymorphisms directly or potentially associated with COVID-19 susceptibility, severity, immune response, and fatal outcomes was done between the Indian population and other major populations (European, African, East Asian, South Asian, and American).

Materials and methods Polymorphisms directly or potentially associated with COVID-19 susceptibility, severity, immune response, and mortality were mined from genetic association studies, comparative genetic studies, expression quantitative trait loci studies among others. Genotype data of these polymorphisms were either sourced from the GenomegaDB™ database of Mapmygenome India Ltd. (sample size = 3054; Indian origin) or were imputed. Polymorphisms with minor allele frequency >= 0.05 and that are in Hardy-Weinberg equilibrium in the Indian population were considered for allele frequency comparison between the Indian population and 1000 Genome population groups.

Results Allele frequencies of 421 polymorphisms were found to be significantly different in the Indian population compared to European, African, East Asian, South Asian, and American populations. 128 polymorphisms were shortlisted based on linkage disequilibrium and were analyzed in detail. Apart from well-studied genes, like ACE2, TMPRSS2, ADAM17, and FURIN, variants from AHSG, IFITM3, PTPN2, CD209, CCL5, HEATR9, SELENBP9, AGO1, HLA-G, MX1, ICAM3, MUC5B, CRP, C1GALT1, and other genes were also found to be significantly different in Indian population. These variants might be implicated in COVID-19 susceptibility and progression.

Conclusion Our comparative study unraveled multiple genetic variants whose allele frequencies were significantly different in the Indian population and might have a potential role in COVID-19 susceptibility, its severity, and fatal outcomes. This study can be very useful for selecting candidate genes/variants for future COVID-19 related genetic association studies.

1 INTRODUCTION

Coronavirus disease - 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV2), has strained the healthcare system and economy of a majority of nations and has crippled the human population [1, 2, 3]. COVID-19 is characterized by a range of clinical features which are categorized as most common, less common, and rare (severe). The most common symptoms are fever, dry cough, and fatigue, while less common symptoms are pneumonia without noticeable hypoxemia, sputum production, sore throat, headache, chest pain, and diarrhea [4, 5]. Acute respiratory distress syndrome, sepsis, acute cardiac injury, heart failure, acute kidney injury, hypoxic encephalopathy are more common in severe cases [4, 5, 6]. Severe patients show elevated levels of pro-inflammatory cytokines, indicating the presence of cytokine storm [4]. Self-reported loss of smell and taste was also observed in some cases [7].

Major risk factors for COVID-19 severity are older age, male gender, and comorbidities. A higher case fatality rate (CFR) has been observed in older adults as compared to the younger population [8, 9, 10, 11, 12]. Relatively fewer female deaths are consistently observed as compared to males [10, 11, 12]. COVID-19 patients with comorbidities like hypertension, obesity, diabetes, and others are more likely to develop severe complications than ones without any underlying diseases [13, 14, 15, 16, 17, 18]. ABO blood groups also seem to be contributing to COVID-19 related risk. While blood group A is associated with an increased risk of severe COVID-19 outcomes, blood group O seems to be protective [19, 20, 21].

In addition to the above risk factors, host genetics can modulate susceptibility and severity of the disease by regulating viral entry and host immune response [22, 23]. For example, rs12329760 (p.Val197Met) affects the stability of TMPRSS2 protein, which is implicated in SARS-CoV2 viral entry into host cells. This polymorphism was found to be less frequent in severe COVID-19 cases as compared to others, suggesting its protective role against severe outcomes of COVID-19 [24]. The C allele of rs12252 in the IFITM3 gene that is known for inhibiting influenza virus entry into host cells was found to be a genetic risk factor for COVID-19 hospitalization and severe outcomes [25, 26]. 3p21.31 gene cluster confers genetic susceptibility to COVID-19 with respiratory failure in Italian and Spanish populations [27]. Genetic variants present in immune-related genes like HLA [24, 28, 29, 30], IL-6 [24], TNF-alpha [31], C5 [32, 33] are associated with COVID-19 severity.

While the majority of these studies were done on European and East Asian populations, limited studies were done on the Indian population [34, 35, 36]. Considering the significant role of host genetics in COVID-19 susceptibility and severity in the Indian population, we analyzed the frequencies of the polymorphisms that are directly or indirectly implicated in COVID-19. We have also made a comparison between Indian and other populations to understand allele frequency distribution globally.

2 MATERIALS AND METHODS

2.1 Literature mining and polymorphism selection

Research articles related to COVID-19 genetic associations were searched in Pubmed using keywords such as ‘COVID’, ‘COVID-19’, ‘Corona virus’, ‘GWAS’, ‘genetic susceptibility’, ‘polymorphism’, ‘severity’, ‘susceptibility’ among other relevant terms. A total of 1418 research articles were found, which were thoroughly screened and 99 relevant articles were selected. A total of 1974 polymorphisms were shortlisted from the selected articles.

2.2 Genotype data for Indian population

The GenomegaDB™ database of Mapmygenome India Ltd. [153] was accessed to obtain genotype data for the present study. It is a human polymorphism genotype database developed and owned by Mapmygenome. It contains genotype data of more than 20000 individuals of various ethnicities. Genotype data of 3035 individuals with confirmed Indian origin were considered in this study. For polymorphisms not present in the database, genotypes were imputed with IMPUTE2 using 1000 Genomes Phase3 data as reference [37, 38]. Filtration was performed with an imputation certainty score (Info metric) set at 0.3.

2.3 Genotype data for other populations

Allelic and genotypic frequency data of selected polymorphisms for African (AFR), East Asian (EAS), European (EUR), South Asian (SAS), and American (AMR) populations were taken from 1000 Genomes Phase 3 data [38].

2.4 Statistical analysis

Polymorphisms having minor allele frequency (MAF) greater than 0.05 in the Indian population (study population) and are in Hardy-Weinberg equilibrium (HWE) (p>0.001) in the Indian population were considered. Pearson’s chi-square test was conducted to compare allele frequencies between the Indian population and other populations (AFR, AMR, EUR, EAS, SAS). False discovery rate (FDR) was applied to correct for multiple comparisons. These statistical tests were done with the R packages HardyWeinberg and stats [39]. LDLink tool [40] was used to calculate linkage disequilibrium (LD) among the polymorphisms.

2.5 eQTL data

To analyze the effect of polymorphisms on gene expressions, expression quantitative trait loci (eQTL) data from publicly available GTEx Project portal was used [41]

3 RESULTS

Out of 1974 shortlisted polymorphisms, 936 polymorphisms had genotype information, either from GenomegaDB™ or from imputation. Among them, 670 polymorphisms that had MAF>=0.05 in the Indian population were considered for further analysis. Followed by this, 589 polymorphisms that were in HWE (p>0.001) were selected. Their allele frequencies in the Indian population were compared with those in other populations using Pearson’s chi-square test of significance (Supplementary File 1, Supplementary Table 1). 421 polymorphisms had significant differences (FDR <= 0.01) in at least three populations with respect to the Indian population (Supplementary File 1, Supplementary Table 2). To rule out redundancy, LD blocks were obtained, and finally, 128 representative polymorphisms were considered to discuss in detail (Supplementary File 2).

Polymorphisms were categorized based on their effect on susceptibility to COVID-19, immune response to SARS-CoV2 infection, COVID-19 severity, mortality related to COVID-19, and comorbidities. Fifty polymorphisms directly or indirectly associated with COVID-19 susceptibility (Table 1), eighteen polymorphisms implicated in the immune response to SARS-CoV2 infection (Table 2), fifty-eight polymorphisms directly or indirectly associated with COVID-19 severity (Table 3), nine polymorphisms associated with COVID-19 related mortality/fatal outcomes (Table 4), and twelve polymorphisms associated with comorbidities of COVID-19 (Table 5) were analyzed.

View this table:
Table 1:

Genetic variants related to COVID-19 susceptibility.

p Effect allele frequency in Indian population. q EAF (India) compared with EAF in other populations (IND – India, EUR – Europe, AMR – America, SAS – South Asia, AFR – Africa, EAS – East Asia. ‘=’ denotes no significant difference between EAF of Indian and the other population. (EA – effect allele, OA – other allele, Ref – references).

View this table:
Table 2:

Genetic variants related to host immune response to SARS-CoV2 infection.

p Effect allele frequency in Indian population. q EAF (India) compared with EAF in other populations (IND – India, EUR – Europe, AMR – America, SAS – South Asia, AFR – Africa, EAS – East Asia. ‘=’ denotes no significant difference between EAF of Indian and the other population. (EA – effect allele, OA – other allele, Ref – references).

View this table:
Table 3:

Genetic variants related to COVID-19 severity.

p Effect allele frequency in Indian population. q EAF (India) compared with EAF in other populations (IND – India, EUR – Europe, AMR – America, SAS – South Asia, AFR – Africa, EAS – East Asia. ‘=’ denotes no significant difference between EAF of Indian and the other population. (EA – effect allele, OA – other allele, Ref – references).

View this table:
Table 4:

Genetic variants related to COVID-19 related fatal outcomes or mortality.

p Effect allele frequency in Indian population. q EAF (India) compared with EAF in other populations (IND – India, EUR – Europe, AMR – America, SAS – South Asia, AFR – Africa, EAS – East Asia. ‘=’ denotes no significant difference between EAF of Indian and the other population. (EA – effect allele, OA – other allele, Ref – references).

View this table:
Table 5:

Genetic variants related to comorbidities that are risk factors of COVID-19 susceptibility/severity.

p Effect allele frequency in Indian population. q EAF (India) compared with EAF in other populations (IND – India, EUR – Europe, AMR – America, SAS – South Asia, AFR – Africa, EAS – East Asia. ‘=’ denotes no significant difference between EAF of Indian and the other population. (EA – effect allele, OA – other allele, Ref – references).

Comparing the risk allele frequencies of a variant between multiple populations can help gain insight into relative genetic predisposition to the associated condition at the population level [42, 43]. In the absence of case-control studies, determining the number of risk variants for different populations might help understand the cumulative genetic effect, hence simplifying the comparison. Here, we applied this approach to ‘COVID-19 susceptibility’, ‘COVID-19 severity’ and ‘COVID-19 related mortality’ categories. Risk conferring variants were assigned to the populations where their frequencies were either highest or lowest. For each population, the number of variants with the highest risk allele frequency and lowest risk allele frequency was counted (Supplementary File 1, Supplementary Table 3). In the ‘COVID-19 susceptibility’ category, the number of variants with the highest risk allele frequency was less than the variants with the lowest risk allele frequency in the IND population. A similar trend was observed in EAS and AFR populations. However, an opposite trend was observed in EUR and AMR populations (Fig. 1A). In IND and AFR populations, COVID-19 severity-related variants with the highest risk allele frequencies were more than the lowest frequency variants, while in EAS, EUR, and AMR populations this was found to be opposite (Fig. 1B). The number of variants associated with COVID-19 related mortality and having the highest risk allele frequency was less than the variants with the lowest risk allele frequency in IND, EAS, and AFR populations, while in SAS and AMR only the highest frequency variants were observed (Fig. 1C).

Figure 1
Figure 1

Comparison of populations based on the number of variants with highest / lowest risk allele frequency related to (A) Susceptibility to COVID-19, (B) COVID-19 severity, and (C) COVID-19 related mortality or fatal outcomes. IND – India, EUR – Europe, AMR

4 DISCUSSION

4.1 COVID-19 susceptibility

SARS-CoV-2 gains entry into human cells by binding its spike protein to ACE2 receptors. ACE2, a part of the renin-angiotensin-aldosterone system (RAAS), is crucial in regulating blood pressure and maintaining electrolyte balance in the body, physiology of the heart, kidneys, and lungs [44, 45]. Genetic variations in ACE2 are known to be associated with its increased expression levels in COVID-19 patients. These variants affect ACE2 transcription/translation and also alter binding affinity to SARS-CoV2 spike protein, thereby affecting the susceptibility to SARS-CoV-2 infection [46, 47]. Six ACE2 polymorphisms (rs2285666 [A], rs4240157 [T], rs4646188 [G], rs2158083 [T], rs1978124 [C] and rs233574 [T]), which are known to be associated with increased ACE2 expression, were found to have allele frequencies significantly different in Indian population as compared to others [48, 49, 41, 50, 51, 52]. Their effect allele frequencies in Indian population are 0.459, 0.69, 0.062, 0.76, 0.724 and 0.176, respectively (Table 1). For four of these variants, effect allele frequencies in EAS are highest suggesting that the EAS population might be predisposed to an increased susceptibility to COVID-19. In addition, the frequencies of rs1996225 [T] and rs4060 [A] of CA5BP1 gene and rs1893217 [G] of PTPN2 gene associated with increased expression of ACE2 are also highest in EAS. IND population has intermediate frequencies for most of these variants indicating moderate susceptibility, while EUR has the lowest frequencies indicating reduced susceptibility.

ACE (angiotensin-converting enzyme) is a vital part of the vascular system. It negatively regulates ACE2 and causes vasoconstriction. Alu Insertion in the ACE coding region inhibits ACE expression, while deletion promotes ACE expression. Increased ACE2 expression is observed when homozygous Alu insertion is present in the ACE gene and vice-versa. rs4343 is in high LD with this Alu element and thus used as its tag SNP [53]. The A and G alleles of rs4343 correspond to Alu insertion and deletion, respectively [54]. Thus A allele signifies reduced ACE expression and consequently increased ACE2 expression, potentially leading to increased SARS-CoV-2 susceptibility. In Indians, the frequency of the A allele (0.604) is significantly higher than Europeans (0.435) but lesser than other populations (Table 1).

On infection with SARS-CoV-2, the ADAM17 shedding is activated, leading to the release of ACE2 from the cell membrane into serum – thus inhibiting the virus infection. But, this effect would be compromised, if the infection rate is high [55, 56, 57, 58]. Thus ADAM17 mediated ACE2 levels may modulate COVID-19 susceptibility. ADAM17 releases the precursor TNF-α from the membrane to its active form – which is a crucial player in triggering an inflammatory response, leading to cytokine storm and is associated with severe lung damage in COVID-19 patients [59,60]. Thus, ADAM17 might be playing role in ACE2 mediated COVID-19 susceptibility and TNF-α mediated COVID-19 severity. rs55790676 [G] and rs1524668 [C] associated with decreased ADAM17 expression have high frequencies in IND population (0.925 and 0.403, respectively), lesser only than EAS, indicating increased susceptibility of COVID-19 in IND population.

FURIN is an endoprotease that is implicated in cleaving the SARS-CoV2 spike protein at the S1/S2 site and this cleavage is crucial for viral entry into pulmonary cells [61]. Increased FURIN expression affects monocyte adhesion and transendothelial migration [62] that can lead to tissue damage which is seen in severe COVID-19 patients [63]. In this study, three genetic variants that affect FURIN expression were identified whose allele frequencies are significantly different in the IND population. rs4702 [A] and rs4932178 [T], present in FURIN coding region, are associated with increased FURIN expression [64, 41]. It was also found that rs4702 [A] is associated with increased SARS-CoV2 infection [65]. The frequency of rs4702 [A] in IND (0.499) is one of the lowest suggesting relatively lesser COVID-19 susceptibility in the IND population. The frequency of rs4932178 [T] in the IND population (0.276) is intermediate as compared to others, indicating moderate COVID-19 susceptibility in IND. rs17514846 [A] is associated with the increased FURIN expression in vascular endothelial cells, where it affects monocyte adhesion and transendothelial migration [62]. Recruitment of monocytes and their transendothelial migration can lead to tissue damage which is seen in severe COVID-19 patients [63, 66]. The frequency of rs17514846 [A] in IND (0.371) is significantly higher than EAS and AMR populations and lesser than EUR (Table 3).

IFITM-family proteins are major players in antiviral responses [67]. Severe inflammation and enhanced activation of natural killer cells are observed in influenza-infected IFITM3 deficient mice [68]. IFITM3 is up-regulated in SARS-CoV2 infected lung epithelial cells of COVID-19 patients [69], and IFITM3 seems to restrict SARS-CoV2 infection by modulating the cell membrane properties [70]. This indicates that IFITM3 might be modulating susceptibility to SARS-CoV2 infection. rs11246066 [A] allele is associated with increased IFITM3 expression in whole blood and it is also an eQTL of other IFITM family genes in multiple tissues [71]. rs11246066 [A] allele frequency in the Indian population (0.189) is significantly greater only than the African population. rs9666637 [T] and rs7931303 [G] are associated with increased IFITM2 expression. rs9666637 [T] allele frequency in the Indian population (0.912) is highest among all populations, while rs7931303 [G] allele frequency in the Indian population (0.398) is higher only than AFR. Considering the significance of the IFITM family, Indian population might be less susceptible to COVID-19 due to rs9666637 [T].

CTSL gene is involved in many biological processes such as antigen processing and presentation, proteolysis, macrophage apoptotic process, and immune response. It is associated with many diseases such as cancer, diabetes, kidney failure, and viral infections [72]. It regulates viral entry into host cells and is up-regulated during COVID-19 infection suggesting its potential role in COVID-19 susceptibility and severity [72, 73]. rs3128509 [G] is associated with decreased CTSL expression in various tissues [41] and its frequency is significantly lesser in Indians (0.809) compared to African and East Asian populations but greater than European and American populations. This suggests that the Indian population might be more susceptible to COVID-19 than European and American populations but lesser than African and East populations.

Progesterone acts as a potent immunomodulator in regulating innate and adaptive immune responses and vascular system functions. Progesterone receptors (PGRs) are intracellular receptors that on binding to progesterone or its derivative regulate target gene expression. An Alu insertion in intron 7 of the PGR gene reduces transcript stability, consequently affecting PGR protein structure and function [74]. As a result of this insertion, PGR modulated differential expression of ACE2 may potentially affect SARS-CoV2 infection susceptibility. This Alu insertion is in complete LD with rs1042838. A and G alleles of rs1042838 correspond to Alu insertion and deletion, respectively [53]. The frequency of rs1042838 [A] in IND (0.078) is significantly lesser than AMR (0.137) and EUR (0.179) populations while greater than AFR (0.006) and EAS (0.01) populations.

TMPRSS2 is a serine protease that plays an important role in SARS-COV2 entry into the host cell. The viral spike (S) protein on binding to ACE2 on the host cell is cleaved at its S1/S2 position by TMPRSS2 thus facilitating viral entry into the host cell [75]. Increased SARS-CoV2 infection correlates with increased TMPRSS2 expression [76]. Eleven polymorphisms (rs35477708 [GA], rs468259 [C], rs363981 [T], rs1638369 [T], rs469288 [G], rs468699 [C], rs462698 [A], rs8134378 [G], rs467375 [A], rs4818239 [C], rs35899679 [A]) whose allele frequencies are significantly in Indian population are associated with increased TMPRSS2 expression [77, 64, 47, 41]. Except for rs8134378 [G], frequencies of remaining variants are highest in EUR and lowest in EAS, suggesting EUR might be at increased susceptibility of COVID-19 while EAS at lowest. Their frequencies in IND are intermediate thus potentially conferring moderate susceptibility in the IND population.

Zinc deficiency is associated with increased COVID-19 susceptibility in the Asian population [78]. Among the genetic variants associated with decreased zinc levels (rs2120019 [C], rs1532423 [G], rs4826508 [C]) and thereby increased susceptibility to COVID-19, rs1532423 [G] from CA1 gene and rs4826508 [C] from the NBDY gene have the lowest frequencies in IND (0.494 and 0.273, respectively), which might be conferring reduced susceptibility to COVID-19 in Indian population. However, rs2120019 [C] from the PPCDC gene might be having an opposite effect as its frequency in IND (0.62) is highest.

4.2 Immune response to SARS-CoV2 infection

IFIH1 gene encodes a protein that recognizes the viral RNA and initiates immune and proinflammatory responses. rs1990760 [T], which is present in the IFIH1 coding region, is associated with autoimmune disorders and protects against viral infection [79]. T allele frequency in Indians is 0.516, second only to Europeans (Table 2). Thus, this might be conferring increased protection to the Indian population against viral infections, including SARS-CoV2.

The chemokines CCL5, CCL4, and CCL3 play an important role in inflammation where they recruit immune cells [80, 81]. They are expressed during respiratory viral infections, and their expression levels are associated with disease severity [82, 83, 84]. In severely affected COVID-19 patients, their expression levels are significantly high, leading to liver toxicity and kidney failure, which are the most common complications associated with COVID-19 infection [82, 83, 84, 85]. rs2526327 [A] in RDM1 gene, rs1994182 [G] in MMP28 gene, rs3826404 [G] in MMP28 gene, rs2107538 [T] and rs3817655 [T] in CCL5 genes are associated with decreased CCL5 expression in whole blood [71] while rs4239252 [A] in TAF15 gene is associated with increased expression of CCL5 in whole blood [71]. All of these alleles are minor alleles in the Indian population. rs3817655, which lies in the CCL5 coding gene, is also associated with SARS-COV susceptibility [42]. The frequency of rs3817655 [T] allele in the Indian population (0.127) is least as compared to other populations.

4.3 COVID-19 severity

IGFBP2 is involved in the regulation of insulin-like growth factor receptor signaling pathways, and its expression level is used as a marker for many cancers. The intronic variant rs2270360 [A] in the IGFBP2 gene was found to be associated with increased COVID-19 severity [86]. The risk allele [A] frequency in the Indian population is 0.927 which is significantly higher than other populations, indicating the predisposition of the Indian population to the severity of the disease.

Low calcium levels in the serum are associated with COVID-19 severity, and maintaining proper calcium is a prerequisite to managing COVID-19 in the initial infection stage. RYR3 is a part of the calcium channel complex and releases calcium for intracellular activities [87]. rs2229117 [G] in the RYR3 gene is shown to be associated with increased COVID-19 severity [86]. G allele frequency in the Indian population (0.913) is higher than American and European populations but lesser than African and East Asian populations (Table 3). Thus this variant might be conferring a moderate risk of COVID-19 severity in the Indian population.

CCL2 and CCR1 play major roles in immune and inflammatory responses. CCL2 is a chemo-attractant cytokine that modulates the recruitment of monocytes, T cells, B cells, natural killer cells, macrophages, and dendritic cells [88]. Increased CCL2 levels are observed in severe COVID-19 patients as compared to less severe COVID-19 patients [89]. CCR1 is a chemokine receptor that is strongly expressed in monocytes and macrophages and promotes their infiltration into the lungs in severe COVID-19 cases [90]. rs1024611 [G] and rs1015164 [G] alleles are associated with increased CCL2 expression [91] and increased CCR1 expression in whole blood [63], respectively. rs1024611 [G] frequency in Indians (0.316) is significantly greater than only the African population, while rs1015164 [G] frequency in Indians (0.753) is significantly greater than only the European population (Table 3).

MX1 is known to be implicated in the generation of protective immune responses against influenza infection [92]. Increased MX1 expression in the nasopharynx of COVID-19 patients is observed to be proportional to SARS-CoV2 viral load. However, its expression seems to reduce with increased age, suggesting inadequate antiviral immune response in older adults causing severe COVID-19 [92]. These results suggest that increased expression of MX1 might be restricting the COVID-19 severity. Six polymorphisms (rs35477708 [G], rs468259 [G], rs363981 [G], rs1638369 [G], rs469288 [A], rs468699 [T], rs462698 [G]) associated with decreased MX1 expression [41, 47] might be increasing risk of COVID-19 severity. Effect allele frequencies of each of these variants are highest in EAS and lowest in the EUR population. This indicates that the EAS population might be vulnerable to increased risk of COVID-19 severity, while EUR and IND populations might be at reduced and moderate risk, respectively.

TNF encodes a proinflammatory cytokine secreted by macrophages is a major player contributing to the development of cytokine storms. rs1800630 [A] in the TNF gene is associated with an increased risk of developing acute respiratory distress syndrome (ARDS) [93]. The frequency of risk allele [A] in the Indian population (0.283) is highest as compared to other populations, suggesting that the allele might be conferring increased risk of COVID-19 severity to the Indian population.

AHSG levels are critical for regulating macrophage deactivation. Decreased AHSG leads to impaired macrophage deactivation thus causing excess pro-inflammatory cytokine release in SARS-COV infection. rs2248690 [T] is associated with increased AHSG levels and decreased SARS-COV infection severity [94]. T allele frequency in the Indian population is 0.17 which is the least as compared to other populations, indicating that the Indian population might be at an increased risk of COVID-19 severity.

rs10735079 in OAS gene cluster (OAS1, OAS2, OAS3) is associated with antiviral mechanisms by producing 2′,5′-oligoadenylate (2-5A), which is a mediator in the antiviral process. This mediator activates RNaseL which degrades double-stranded RNA of corona virus [95]. rs10735079 [A] allele is associated with an increased risk of severe COVID-19. rs10735079 [A] allele corresponds to lower OAS1 activity and higher odds of severe COVID-19 [95]. A allele frequency in the Indian population (0.698) is lower than African, American, and East Asian populations but greater than Europeans, suggesting that the Indian population might be at a reduced risk of COVID-19 severity.

Decreased levels of E-selectin and IL-3Ra proteins and increased levels of B3GN2 and C1GLC proteins are associated with increased COVID-19 severity [96]. rs2519093 [T] is associated with decreased E-selectin and IL-3Ra protein levels and increased B3GN2 and C1GLC protein levels. Thus, rs2519093 [T] might be increasing COVID-19 severity through modulating these protein levels. T allele frequency in the Indian population (0.128) (Table 3), is greater than only the African population, suggesting that Indian population might be at a reduced risk of COVID-19 severity.

Vitamin D deficiency is associated with COVID-19 positivity and severity [97, 98]. GC gene encodes a protein that binds to vitamin D and transports it to targeted tissues. rs1155563 [C] allele, that is present in the GC gene, is associated with decreased serum vitamin-D levels [99], and its frequency in the Indian population (0.29) is greater than that of African, American, and European populations (Table 3). This suggests that rs1155563 [C] might be increasing COVID-19 susceptibility and severity in the Indian population through reduced vitamin-D levels.

4.4 COVID-19 related mortality or fatal outcomes

Kim YC and Jeong BH [71] found the frequencies of T allele of rs2074192 in the ACE2 gene, and G allele of rs2298659 in the TMPRSS2 gene to be positively correlated with case fatality rate. Indians have lowest frequency of rs2074192 [T] (0.222) compared to Africans (0.351), Americans (0.405), East Asians (0.43) and Europeans (0.432). But they have highest frequency of rs2298659 [G] (0.834) compared to Africans (0.825), Americans (0.782), Europeans (0.77) and East Asians (0.751). Indians have lesser frequency of G allele of rs6598045 in the IFITM3 gene (0.159), which is associated with decreased case fatality rate, compared to Africans (0.299) and Americans (0.222).

DES/SPEG genes code for muscle-specific proteins and mutations in these genes are involved with cardiomyopathies [100, 101]. Acute damage to the heart is a common complication in COVID-19 patients. A allele of rs71040457 that is located downstream of the DES and upstream of the SPEG genes was found to be associated with an increased risk of COVID-19 mortality in the white British ancestry population [102]. While East Asians have the lowest frequency of this allele (0.177), Indians have a lesser frequency (0.276) compared to European (0.376), American (0.385), and African (0.939) populations.

SLC39A10 gene plays an important role in mediating immune cell homeostasis. It has been reported to facilitate anti-apoptotic signaling during early B-cell development, modulate B-cell receptor signal strength, and control macrophage survival. rs113892140 located in this gene is associated with an increased risk of COVID-19 mortality [102]. Risk allele [A] frequency in the Indian population is 0.078 (Table 4), which is significantly greater than only the European population (0.046). Its frequency is highest in the African population (0.256).

4.5 COVID-19 related comorbidities

Twelve polymorphisms associated with comorbidities of COVID-19 were also analyzed (Table 5). Hypertension, coronary artery disease, type 2 diabetes are among the major comorbidities of COVID-19 severity. rs2074192 [T] is associated with an increased risk of developing hypertension [49]. T allele frequency in the Indian population (0.222) is least as compared to other populations.

5 CONCLUSION

The potential role of several polymorphisms in COVID-19 susceptibility and severity suggests that host genetics plays an important role in the pathology and progression of the infection. We found multiple genetic variants that might be affecting the COVID-19 susceptibility, immune response, severity, and mortality. Some of these variants were observed in genetic association studies, while others were found to be relevant based on gene regulation and signaling pathways.

COVID-19 positivity rate in India is one of the least in the world despite India being the second most populated nation [154, 155]. Due to the high population density in India, the spread of an airborne pathogen can be limited only to a certain extent [103]. Hence, a low COVID-19 positivity rate in India might be due to the lower genetic predisposition of Indians to COVID-19 susceptibility. The fatality rate of COVID-19 in India was relatively high during the peak phases of the first and second waves. However, when the peaks subsided the fatality rate reduced significantly. Inadequate medical facilities seem to be one of the major reasons which caused preventable deaths during these periods. [104]. Thus, the role of genetics in COVID-19 severity risk in the Indian population remains unclear. More detailed studies are warranted to confirm the COVID-19 related relevance of the variants discussed in this article. The current study will act as a good source to shortlist variants/genes for conducting genetic association studies to assess COVID-19 susceptibility, its severity, and mortality.

Data Availability

All data produced in the present study are available upon reasonable request to the authors

6 REFERENCES

  1. 1.↵
    Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–273. doi:10.1038/s41586-020-2012-7
    OpenUrlCrossRefPubMed
  2. 2.↵
    Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–733. doi:10.1056/NEJMoa2001017
    OpenUrlCrossRefPubMed
  3. 3.↵
    Guo YR, Cao QD, Hong ZS, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res. 2020;7(1):11. Published 2020 Mar 13. doi:10.1186/s40779-020-00240-0
    OpenUrlCrossRefPubMed
  4. 4.↵
    Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China [published correction appears in Lancet [2020 Jan 30;:]. Lancet. 2020;395(10223):497–506. doi:10.1016/S0140-6736(20)30183-5
    OpenUrlCrossRefPubMed
  5. 5.↵
    Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513. doi:10.1016/S0140-6736(20)30211-7
    OpenUrlCrossRefPubMed
  6. 6.↵
    Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study [published correction appears in BMJ. 2020 Mar 31;368:m1295]. BMJ. 2020;368:m1091. Published 2020 Mar 26. doi:10.1136/bmj.m1091
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    Giacomelli A, Pezzati L, Conti F, et al. Self-reported Olfactory and Taste Disorders in Patients With Severe Acute Respiratory Coronavirus 2 Infection: A Cross-sectional Study. Clin Infect Dis. 2020;71(15):889–890. doi:10.1093/cid/ciaa330
    OpenUrlCrossRefPubMed
  8. 8.↵
    Zhang JJ, Cao YY, Tan G, et al. Clinical, radiological, and laboratory characteristics and risk factors for severity and mortality of 289 hospitalized COVID-19 patients. Allergy. 2021;76(2):533–550. doi:10.1111/all.14496
    OpenUrlCrossRef
  9. 9.↵
    Rubin SJS, Falkson SR, Degner NR, Blish C. Clinical characteristics associated with COVID-19 severity in California. J Clin Transl Sci. 2020;5(1):e3. Published 2020 Apr 16. doi:10.1017/cts.2020.40
    OpenUrlCrossRef
  10. 10.↵
    Riccardo F, Ajelli M, Andrianou XD, et al. Epidemiological characteristics of COVID-19 cases and estimates of the reproductive numbers 1 month into the epidemic, Italy, 28 January to 31 March 2020. Euro Surveill. 2020;25(49):2000790. doi:10.2807/1560-7917.ES.2020.25.49.2000790
    OpenUrlCrossRefPubMed
  11. 11.↵
    Cao M, Zhang D, Wang Y, et al. Clinical Features of Patients Infected with the 2019 Novel Coronavirus (COVID-19) in Shanghai, China. Preprint. medRxiv. 2020;2020.03.04.20030395. Published 2020 Mar 6. doi:10.1101/2020.03.04.20030395
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    Jin JM, Bai P, He W, et al. Gender Differences in Patients With COVID-19: Focus on Severity and Mortality. Front Public Health. 2020;8:152. Published 2020 Apr 29. doi:10.3389/fpubh.2020.00152
    OpenUrlCrossRefPubMed
  13. 13.↵
    Guo L, Shi Z, Zhang Y, et al. Comorbid diabetes and the risk of disease severity or death among 8807 COVID-19 patients in China: A meta-analysis. Diabetes Res Clin Pract. 2020;166:108346. doi:10.1016/j.diabres.2020.108346
    OpenUrlCrossRef
  14. 14.↵
    Bode B, Garrett V, Messler J, et al. Glycemic Characteristics and Clinical Outcomes of COVID-19 Patients Hospitalized in the United States [published correction appears in J Diabetes Sci Technol. 2020 Jun 10;:1932296820932678]. J Diabetes Sci Technol. 2020;14(4):813–821. doi:10.1177/1932296820924469
    OpenUrlCrossRef
  15. 15.↵
    Huang S, Wang J, Liu F, et al. COVID-19 patients with hypertension have more severe disease: a multicenter retrospective observational study. Hypertens Res. 2020;43(8):824–831. doi:10.1038/s41440-020-0485-2
    OpenUrlCrossRef
  16. 16.↵
    Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China [published correction appears in JAMA. 2021 Mar 16;325(11):1113]. JAMA. 2020;323(11):1061–1069. doi:10.1001/jama.2020.1585
    OpenUrlCrossRefPubMed
  17. 17.↵
    Ran J, Song Y, Zhuang Z, et al. Blood pressure control and adverse outcomes of COVID-19 infection in patients with concomitant hypertension in Wuhan, China. Hypertens Res. 2020;43(11):1267–1276. doi:10.1038/s41440-020-00541-w
    OpenUrlCrossRef
  18. 18.↵
    Fresán U, Guevara M, Elía F, et al. Independent Role of Severe Obesity as a Risk Factor for COVID-19 Hospitalization: A Spanish Population-Based Cohort Study. Obesity (Silver Spring). 2021;29(1):29–37. doi:10.1002/oby.23029
    OpenUrlCrossRefPubMed
  19. 19.↵
    Hoiland RL, Fergusson NA, Mitra AR, et al. The association of ABO blood group with indices of disease severity and multiorgan dysfunction in COVID-19. Blood Adv. 2020;4(20):4981–4989. doi:10.1182/bloodadvances.2020002623
    OpenUrlCrossRefPubMed
  20. 20.↵
    Pourali F, Afshari M, Alizadeh-Navaei R, Javidnia J, Moosazadeh M, Hessami A. Relationship between blood group and risk of infection and death in COVID-19: a live meta-analysis. New Microbes New Infect. 2020;37:100743. doi:10.1016/j.nmni.2020.100743
    OpenUrlCrossRef
  21. 21.↵
    Garg I, Srivastava S, Dogra V, et al. Potential association of COVID-19 and ABO blood group: An Indian study. Microb Pathog. 2021;158:105008. doi:10.1016/j.micpath.2021.105008
    OpenUrlCrossRef
  22. 22.↵
    Kwok AJ, Mentzer A, Knight JC. Host genetics and infectious disease: new tools, insights and translational opportunities. Nat Rev Genet. 2021;22(3):137–153. doi:10.1038/s41576-020-00297-6
    OpenUrlCrossRef
  23. 23.↵
    Di Maria E, Latini A, Borgiani P, Novelli G. Genetic variants of the human host influencing the coronavirus-associated phenotypes (SARS, MERS and COVID-19): rapid systematic review and field synopsis. Hum Genomics. 2020;14(1):30. Published 2020 Sep 11. doi:10.1186/s40246-020-00280-6
    OpenUrlCrossRefPubMed
  24. 24.↵
    Wang F, Huang S, Gao R, et al. Initial whole-genome sequencing and analysis of the host genetic contribution to COVID-19 severity and susceptibility. Cell Discov. 2020;6(1):83. Published 2020 Nov 10. doi:10.1038/s41421-020-00231-4
    OpenUrlCrossRef
  25. 25.↵
    Gómez J, Albaiceta GM, Cuesta-Llavona E, et al. The Interferon-induced transmembrane protein 3 gene (IFITM3) rs12252 C variant is associated with COVID-19. Cytokine. 2021;137:155354. doi:10.1016/j.cyto.2020.155354
    OpenUrlCrossRef
  26. 26.↵
    Zhang Y, Qin L, Zhao Y, et al. Interferon-Induced Transmembrane Protein 3 Genetic Variant rs12252-C Associated With Disease Severity in Coronavirus Disease 2019. J Infect Dis. 2020;222(1):34–37. doi:10.1093/infdis/jiaa224
    OpenUrlCrossRefPubMed
  27. 27.↵
    Severe Covid-19 GWAS Group, Ellinghaus D, Degenhardt F, et al. Genomewide Association Study of Severe Covid-19 with Respiratory Failure. N Engl J Med. 2020;383(16):1522–1534. doi:10.1056/NEJMoa2020283
    OpenUrlCrossRefPubMed
  28. 28.↵
    Littera R, Campagna M, Deidda S, et al. Human Leukocyte Antigen Complex and Other Immunogenetic and Clinical Factors Influence Susceptibility or Protection to SARS-CoV-2 Infection and Severity of the Disease Course. The Sardinian Experience. Front Immunol. 2020;11:605688. Published 2020 Dec 4. doi:10.3389/fimmu.2020.605688
    OpenUrlCrossRef
  29. 29.↵
    Yung YL, Cheng CK, Chan HY, et al. Association of HLA-B22 serotype with SARS-CoV-2 susceptibility in Hong Kong Chinese patients. HLA. 2021;97(2):127–132. doi:10.1111/tan.14135
    OpenUrlCrossRef
  30. 30.↵
    Amoroso A, Magistroni P, Vespasiano F, et al. HLA and AB0 Polymorphisms May Influence SARS-CoV-2 Infection and COVID-19 Severity. Transplantation. 2021;105(1):193–200. doi:10.1097/TP.0000000000003507
    OpenUrlCrossRefPubMed
  31. 31.↵
    Saleh A, Sultan A, Elashry MA, et al. Association of TNF-α G-308 a Promoter Polymorphism with the Course and Outcome of COVID-19 Patients [published online ahead of print, 2020 Nov 23]. Immunol Invest. 2020;1–12. doi:10.1080/08820139.2020.1851709
    OpenUrlCrossRef
  32. 32.↵
    Java A, Apicelli AJ, Liszewski MK, et al. The complement system in COVID-19: friend and foe?. JCI Insight. 2020;5(15):e140711. Published 2020 Aug 6. doi:10.1172/jci.insight.140711
    OpenUrlCrossRefPubMed
  33. 33.↵
    Valenti L, Griffini S, Lamorte G, et al. Chromosome 3 cluster rs11385942 variant links complement activation with severe COVID-19 [published correction appears in J Autoimmun. 2021 Jun;120:102646]. J Autoimmun. 2021;117:102595. doi:10.1016/j.jaut.2021.102595
    OpenUrlCrossRefPubMed
  34. 34.↵
    Srivastava A, Bandopadhyay A, Das D, et al. Genetic Association of ACE2 rs2285666 Polymorphism With COVID-19 Spatial Distribution in India. Front Genet. 2020;11:564741. Published 2020 Sep 25. doi:10.3389/fgene.2020.564741
    OpenUrlCrossRef
  35. 35.↵
    Ravikanth V, Sasikala M, Naveen V, et al. A variant in TMPRSS2 is associated with decreased disease severity in COVID-19. Meta Gene. 2021;29:100930. doi:10.1016/j.mgene.2021.100930
    OpenUrlCrossRef
  36. 36.↵
    Singh PP, Srivastava A, Sultana GNN, et al. The major genetic risk factor for severe COVID-19 does not show any association among South Asian populations [published correction appears in Sci Rep. 2021 Aug 5;11(1):16296]. Sci Rep. 2021;11(1):12346. Published 2021 Jun 11. doi:10.1038/s41598-021-91711-4
    OpenUrlCrossRef
  37. 37.↵
    Howie B, Marchini J, Stephens M. Genotype imputation with thousands of genomes. G3 (Bethesda). 2011;1(6):457–470. doi:10.1534/g3.111.001198
    OpenUrlCrossRefPubMed
  38. 38.↵
    1000 Genomes Project Consortium, Auton A, Brooks LD, et al. A global reference for human genetic variation. Nature. 2015;526(7571):68–74. doi:10.1038/nature15393
    OpenUrlCrossRefPubMed
  39. 39.↵
    R Core Team (2020). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL https://www.R-project.org/
  40. 40.↵
    Machiela MJ, Chanock SJ. LDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants. Bioinformatics. 2015;31(21):3555–3557. doi:10.1093/bioinformatics/btv402
    OpenUrlCrossRefPubMed
  41. 41.↵
    GTEx Consortium. The Genotype-Tissue Expression (GTEx) project. Nat Genet. 2013;45(6):580–585. doi:10.1038/ng.2653
    OpenUrlCrossRefPubMed
  42. 42.↵
    Smatti MK, Al-Sarraj YA, Albagha O, Yassine HM. Host Genetic Variants Potentially Associated With SARS-CoV-2: A Multi-Population Analysis. Front Genet. 2020;11:578523. Published 2020 Oct 2. doi:10.3389/fgene.2020.578523
    OpenUrlCrossRef
  43. 43.↵
    Secolin R, de Araujo TK, Gonsales MC, et al. Genetic variability in COVID-19-related genes in the Brazilian population. Hum Genome Var. 2021;8:15. Published 2021 Apr 2. doi:10.1038/s41439-021-00146-w
    OpenUrlCrossRef
  44. 44.↵
    Bhalla V, Blish CA, South AM. A historical perspective on ACE2 in the COVID-19 era. J Hum Hypertens. 2021;35(10):935–939. doi:10.1038/s41371-020-00459-3
    OpenUrlCrossRef
  45. 45.↵
    Santos RAS, Sampaio WO, Alzamora AC, et al. The ACE2/Angiotensin-(1-7)/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1-7). Physiol Rev. 2018;98(1):505–553. doi:10.1152/physrev.00023.2016
    OpenUrlCrossRefPubMed
  46. 46.↵
    Calcagnile M, Forgez P, Iannelli A, Bucci C, Alifano M, Alifano P. ACE2 polymorphisms and individual susceptibility to SARS-CoV-2 infection: insights from an in silico study. Preprint. bioRxiv. 2020; 2020.04.23.057042v1. Published 2020 April 24. doi: 10.1101/2020.04.23.057042
    OpenUrlAbstract/FREE Full Text
  47. 47.↵
    Lanjanian H, Moazzam-Jazi M, Hedayati M, et al. SARS-CoV-2 infection susceptibility influenced by ACE2 genetic polymorphisms: insights from Tehran Cardio-Metabolic Genetic Study. Sci Rep. 2021;11(1):1529. Published 2021 Jan 15. doi:10.1038/s41598-020-80325-x
    OpenUrlCrossRef
  48. 48.↵
    Wu YH, Li JY, Wang C, Zhang LM, Qiao H. The ACE2 G8790A Polymorphism: Involvement in Type 2 Diabetes Mellitus Combined with Cerebral Stroke. J Clin Lab Anal. 2017;31(2):e22033. doi:10.1002/jcla.22033
    OpenUrlCrossRefPubMed
  49. 49.↵
    Bosso M, Thanaraj TA, Abu-Farha M, Alanbaei M, Abubaker J, Al-Mulla F. The Two Faces of ACE2: The Role of ACE2 Receptor and Its Polymorphisms in Hypertension and COVID-19. Mol Ther Methods Clin Dev. 2020;18:321–327. Published 2020 Jun 25. doi:10.1016/j.omtm.2020.06.017
    OpenUrlCrossRef
  50. 50.↵
    Brest P, Refae S, Mograbi B, Hofman P, Milano G. Host Polymorphisms May Impact SARS-CoV-2 Infectivity. Trends Genet. 2020;36(11):813–815. doi:10.1016/j.tig.2020.08.003
    OpenUrlCrossRef
  51. 51.↵
    Paniri A, Hosseini MM, Moballegh-Eslam M, Akhavan-Niaki H. Comprehensive in silico identification of impacts of ACE2 SNPs on COVID-19 susceptibility in different populations. Gene Rep. 2021;22:100979. doi:10.1016/j.genrep.2020.100979
    OpenUrlCrossRef
  52. 52.↵
    Pouladi N, Abdolahi S. Investigating the ACE2 polymorphisms in COVID-19 susceptibility: An in silico analysis. Mol Genet Genomic Med. 2021;9(6):e1672. doi:10.1002/mgg3.1672
    OpenUrlCrossRef
  53. 53.↵
    Li M, Schifanella L, Larsen PA. Alu retrotransposons and COVID-19 susceptibility and morbidity. Hum Genomics. 2021;15(1):2. Published 2021 Jan 4. doi:10.1186/s40246-020-00299-9
    OpenUrlCrossRef
  54. 54.↵
    Abdollahi MR, Huang S, Rodriguez S, et al. Homogeneous assay of rs4343, an ACE I/D proxy, and an analysis in the British Women’s Heart and Health Study (BWHHS). Dis Markers. 2008;24(1):11–17. doi:10.1155/2008/813679
    OpenUrlCrossRefPubMedWeb of Science
  55. 55.↵
    Schreiber B, Patel A, Verma A. Shedding light on COVID-19: ADAM17 the missing link?. American Journal of Therapeutics. 2021; 28(3),e358–e360.
    OpenUrl
  56. 56.↵
    Bastolla U, Chambers P, Abia D, García-Bermejo ML, Fresno M. Is Covid-19 severity associated with ACE2 degradation?. Preprint. arXiv. 2021;2102.13210.
  57. 57.↵
    Lambert DW, Yarski M, Warner FJ, et al. Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). J Biol Chem. 2005;280(34):30113–30119. doi:10.1074/jbc.M505111200
    OpenUrlAbstract/FREE Full Text
  58. 58.↵
    Palau V, Riera M, Soler MJ. ADAM17 inhibition may exert a protective effect on COVID-19. Nephrol Dial Transplant. 2020;35(6):1071–1072. doi:10.1093/ndt/gfaa093
    OpenUrlCrossRef
  59. 59.↵
    Gooz M. ADAM-17: the enzyme that does it all. Crit Rev Biochem Mol Biol. 2010;45(2):146–169. doi:10.3109/10409231003628015
    OpenUrlCrossRefPubMedWeb of Science
  60. 60.↵
    Zipeto D, Palmeira JDF, Argañaraz GA, Argañaraz ER. ACE2/ADAM17/TMPRSS2 Interplay May Be the Main Risk Factor for COVID-19. Front Immunol. 2020;11:576745. Published 2020 Oct 7. doi:10.3389/fimmu.2020.576745
    OpenUrlCrossRef
  61. 61.↵
    Hoffmann M, Kleine-Weber H, Pöhlmann S. A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells. Mol Cell. 2020;78(4):779-784.e5. doi:10.1016/j.molcel.2020.04.022
    OpenUrlCrossRefPubMed
  62. 62.↵
    Yang X, Yang W, McVey DG, et al. FURIN Expression in Vascular Endothelial Cells Is Modulated by a Coronary Artery Disease-Associated Genetic Variant and Influences Monocyte Transendothelial Migration. J Am Heart Assoc. 2020;9(4):e014333. doi:10.1161/JAHA.119.014333
    OpenUrlCrossRef
  63. 63.↵
    Meidaninikjeh S, Sabouni N, Marzouni HZ, Bengar S, Khalili A, Jafari R. Monocytes and macrophages in COVID-19: Friends and foes. Life Sci. 2021;269:119010. doi:10.1016/j.lfs.2020.119010
    OpenUrlCrossRef
  64. 64.↵
    Ragia G, Manolopoulos VG. Assessing COVID-19 susceptibility through analysis of the genetic and epigenetic diversity of ACE2-mediated SARS-CoV-2 entry. Pharmacogenomics. 2020;21(18):1311–1329. doi:10.2217/pgs-2020-0092
    OpenUrlCrossRef
  65. 65.↵
    Dobrindt K, Hoagland DA, Seah C, et al. Common genetic variation in humans impacts in vitro susceptibility to SARS-CoV-2 infection. Preprint. bioRxiv. 2020;2020.09.20.300574. Published 2020 Sep 21. doi:10.1101/2020.09.20.300574
    OpenUrlAbstract/FREE Full Text
  66. 66.↵
    Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417–1418. doi:10.1016/S0140-6736(20)30937-5
    OpenUrlCrossRefPubMed
  67. 67.↵
    Bailey CC, Zhong G, Huang IC, Farzan M. IFITM-Family Proteins: The Cell’s First Line of Antiviral Defense. Annu Rev Virol. 2014;1:261–283. doi:10.1146/annurev-virology-031413-085537
    OpenUrlCrossRefPubMed
  68. 68.↵
    Sun Q, Lei N, Lu J, et al. Interferon-induced Transmembrane Protein 3 Prevents Acute Influenza Pathogenesis in Mice. Biomed Environ Sci. 2020;33(5):295–305. doi:10.3967/bes2020.041
    OpenUrlCrossRef
  69. 69.↵
    Hachim MY, Al Heialy S, Hachim IY, et al. Interferon-Induced Transmembrane Protein (IFITM3) Is Upregulated Explicitly in SARS-CoV-2 Infected Lung Epithelial Cells. Front Immunol. 2020;11:1372. Published 2020 Jun 10. doi:10.3389/fimmu.2020.01372
    OpenUrlCrossRefPubMed
  70. 70.↵
    Shi G, Kenney AD, Kudryashova E, et al. Opposing activities of IFITM proteins in SARS-CoV-2 infection. EMBO J. 2021;40(3):e106501. doi:10.15252/embj.2020106501
    OpenUrlCrossRefPubMed
  71. 71.↵
    Kim YC, Jeong BH. Strong Correlation between the Case Fatality Rate of COVID-19 and the rs6598045 Single Nucleotide Polymorphism (SNP) of the Interferon-Induced Transmembrane Protein 3 (IFITM3) Gene at the Population-Level. Genes (Basel). 2020;12(1):42. Published 2020 Dec 30. doi:10.3390/genes12010042
    OpenUrlCrossRef
  72. 72.↵
    Gomes CP, Fernandes DE, Casimiro F, et al. Cathepsin L in COVID-19: From Pharmacological Evidences to Genetics. Front Cell Infect Microbiol. 2020;10:589505. Published 2020 Dec 8. doi:10.3389/fcimb.2020.589505
    OpenUrlCrossRef
  73. 73.↵
    Zhao MM, Yang WL, Yang FY, et al. Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development. Signal Transduct Target Ther. 2021;6(1):134. Published 2021 Mar 27. doi:10.1038/s41392-021-00558-8
    OpenUrlCrossRefPubMed
  74. 74.↵
    Romano A, Delvoux B, Fischer DC, Groothuis P. The PROGINS polymorphism of the human progesterone receptor diminishes the response to progesterone. J Mol Endocrinol. 2007;38(1-2):331-350. doi:10.1677/jme.1.02170
    OpenUrlAbstract/FREE Full Text
  75. 75.↵
    Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271-280.e8. doi:10.1016/j.cell.2020.02.052
    OpenUrlCrossRefPubMed
  76. 76.↵
    Sarker J, Das P, Sarker S, Roy AK, Momen AZMR. A Review on Expression, Pathological Roles, and Inhibition of TMPRSS2, the Serine Protease Responsible for SARS-CoV-2 Spike Protein Activation. Scientifica (Cairo). 2021;2021:2706789. Published 2021 Jul 24. doi:10.1155/2021/2706789
    OpenUrlCrossRef
  77. 77.↵
    Clinckemalie L, Spans L, Dubois V, et al. Androgen regulation of the TMPRSS2 gene and the effect of a SNP in an androgen response element. Mol Endocrinol. 2013;27(12):2028–2040. doi:10.1210/me.2013-1098
    OpenUrlCrossRefPubMed
  78. 78.↵
    Ali N, Fariha KA, Islam F, et al. Assessment of the role of zinc in the prevention of COVID-19 infections and mortality: A retrospective study in the Asian and European population. J Med Virol. 2021;93(7):4326–4333. doi:10.1002/jmv.26932
    OpenUrlCrossRef
  79. 79.↵
    Gorman JA, Hundhausen C, Errett JS, et al. The A946T variant of the RNA sensor IFIH1 mediates an interferon program that limits viral infection but increases the risk for autoimmunity. Nat Immunol. 2017;18(7):744–752. doi:10.1038/ni.3766
    OpenUrlCrossRef
  80. 80.↵
    Maurer M, von Stebut E. Macrophage inflammatory protein-1. Int J Biochem Cell Biol. 2004;36(10):1882–1886. doi:10.1016/j.biocel.2003.10.019
    OpenUrlCrossRefPubMedWeb of Science
  81. 81.↵
    Krensky AM, Ahn YT. Mechanisms of disease: regulation of RANTES (CCL5) in renal disease. Nat Clin Pract Nephrol. 2007;3(3):164–170. doi:10.1038/ncpneph0418
    OpenUrlCrossRefPubMedWeb of Science
  82. 82.↵
    Marques RE, Guabiraba R, Russo RC, Teixeira MM. Targeting CCL5 in inflammation. Expert Opin Ther Targets. 2013;17(12):1439–1460. doi:10.1517/14728222.2013.837886
    OpenUrlCrossRefPubMed
  83. 83.↵
    Patterson BK, Seethamraju H, Dhody K, et al. Disruption of the CCL5/RANTES-CCR5 Pathway Restores Immune Homeostasis and Reduces Plasma Viral Load in Critical COVID-19. Preprint. medRxiv. 2020;2020.05.02.20084673. Published 2020 May 5. doi:10.1101/2020.05.02.20084673
    OpenUrlAbstract/FREE Full Text
  84. 84.↵
    Coperchini F, Chiovato L, Ricci G, Croce L, Magri F, Rotondi M. The cytokine storm in COVID-19: Further advances in our understanding the role of specific chemokines involved. Cytokine Growth Factor Rev. 2021;58:82–91. doi:10.1016/j.cytogfr.2020.12.005
    OpenUrlCrossRef
  85. 85.↵
    Patterson BK, Seethamraju H, Dhody K, et al. CCR5 inhibition in critical COVID-19 patients decreases inflammatory cytokines, increases CD8 T-cells, and decreases SARS-CoV2 RNA in plasma by day 14. Int J Infect Dis. 2021;103:25–32. doi:10.1016/j.ijid.2020.10.101
    OpenUrlCrossRefPubMed
  86. 86.↵
    Dite GS, Murphy NM, Allman R. An integrated clinical and genetic model for predicting risk of severe COVID-19: A population-based case-control study. PLoS One. 2021;16(2):e0247205. Published 2021 Feb 16. doi:10.1371/journal.pone.0247205
    OpenUrlCrossRef
  87. 87.↵
    Zhou X, Chen D, Wang L, et al. Low serum calcium: a new, important indicator of COVID-19 patients from mild/moderate to severe/critical [published online ahead of print, 2020 Nov 30]. Biosci Rep. 2020;40(12):BSR20202690. doi:10.1042/BSR20202690
    OpenUrlCrossRef
  88. 88.↵
    Gschwandtner M, Derler R, Midwood KS. More Than Just Attractive: How CCL2 Influences Myeloid Cell Behavior Beyond Chemotaxis. Front Immunol. 2019;10:2759. Published 2019 Dec 13. doi:10.3389/fimmu.2019.02759
    OpenUrlCrossRefPubMed
  89. 89.↵
    Coperchini F, Chiovato L, Croce L, Magri F, Rotondi M. The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system. Cytokine Growth Factor Rev. 2020;53:25–32. doi:10.1016/j.cytogfr.2020.05.003
    OpenUrlCrossRefPubMed
  90. 90.↵
    Stikker B, Stik G, Hendriks RW, Stadhouders R. Severe COVID-19 associated variants linked to chemokine receptor gene control in monocytes and macrophages. Preprint. bioRxiv. 2021;2021.01.22.427813. Published 2021 Jun 11. doi:10.1101/2021.01.22.427813
    OpenUrlAbstract/FREE Full Text
  91. 91.↵
    Pham MH, Bonello GB, Castiblanco J, et al. The rs1024611 regulatory region polymorphism is associated with CCL2 allelic expression imbalance. PLoS One. 2012;7(11):e49498. doi:10.1371/journal.pone.0049498
    OpenUrlCrossRefPubMed
  92. 92.↵
    Bizzotto J, Sanchis P, Abbate M, et al. SARS-CoV-2 Infection Boosts MX1 Antiviral Effector in COVID-19 Patients. iScience. 2020;23(10):101585. doi:10.1016/j.isci.2020.101585
    OpenUrlCrossRef
  93. 93.↵
    Azevedo ZM, Moore DB, Lima FC, et al. Tumor necrosis factor (TNF) and lymphotoxin-alpha (LTA) single nucleotide polymorphisms: importance in ARDS in septic pediatric critically ill patients. Hum Immunol. 2012;73(6):661–667. doi:10.1016/j.humimm.2012.03.007
    OpenUrlCrossRefPubMed
  94. 94.↵
    Zhu X, Wang Y, Zhang H, et al. Genetic variation of the human α-2-Heremans-Schmid glycoprotein (AHSG) gene associated with the risk of SARS-CoV infection. PLoS One. 2011;6(8):e23730. doi:10.1371/journal.pone.0023730
    OpenUrlCrossRefPubMed
  95. 95.↵
    Pairo-Castineira, Erola, Clohisey S, Klaric L, Bretherick AD, Rawlik K, Pasko D, Walker S et al. Nature. 2021; 591(7848):92–98. doi:10.1038/s41586-020-03065-y. Epub 2020 Dec 11.
    OpenUrlCrossRefPubMed
  96. 96.↵
    Zhu J, Wu C, Wu L. Associations Between Genetically Predicted Protein Levels and COVID-19 Severity. J Infect Dis. 2021;223(1):19–22. doi:10.1093/infdis/jiaa660
    OpenUrlCrossRef
  97. 97.↵
    Demir M, Demir F, Aygun H. Vitamin D deficiency is associated with COVID-19 positivity and severity of the disease. J Med Virol. 2021;93(5):2992–2999. doi:10.1002/jmv.26832
    OpenUrlCrossRef
  98. 98.↵
    Weir EK, Thenappan T, Bhargava M, Chen Y. Does vitamin D deficiency increase the severity of COVID-19?. Clin Med (Lond). 2020;20(4):e107–e108. doi:10.7861/clinmed.2020-0301
    OpenUrlAbstract/FREE Full Text
  99. 99.↵
    Galmés S, Serra F, Palou A. Current State of Evidence: Influence of Nutritional and Nutrigenetic Factors on Immunity in the COVID-19 Pandemic Framework. Nutrients. 2020;12(9):2738. Published 2020 Sep 8. doi:10.3390/nu12092738
    OpenUrlCrossRef
  100. 100.↵
    Agrawal PB, Pierson CR, Joshi M, et al. SPEG interacts with myotubularin, and its deficiency causes centronuclear myopathy with dilated cardiomyopathy. Am J Hum Genet. 2014;95(2):218–226. doi:10.1016/j.ajhg.2014.07.004
    OpenUrlCrossRefPubMed
  101. 101.↵
    Brodehl A, Gaertner-Rommel A, Milting H. Molecular insights into cardiomyopathies associated with desmin (DES) mutations. Biophys Rev. 2018;10(4):983–1006. doi:10.1007/s12551-018-0429-0
    OpenUrlCrossRef
  102. 102.↵
    Hu J, Li C, Wang S, Li T, Zhang H. Genetic variants are identified to increase risk of COVID-19 related mortality from UK Biobank data. Preprint. medRxiv. 2020;2020.11.05.20226761. Published 2020 Nov 9. doi:10.1101/2020.11.05.20226761
    OpenUrlAbstract/FREE Full Text
  103. 103.↵
    Bhadra A, Mukherjee A, Sarkar K. Impact of population density on Covid-19 infected and mortality rate in India [published online ahead of print, 2020 Oct 14]. Model Earth Syst Environ. 2020;1–7. doi:10.1007/s40808-020-00984-7
    OpenUrlCrossRef
  104. 104.↵
    Asrani P, Eapen MS, Hassan MI, Sohal SS. Implications of the second wave of COVID-19 in India. Lancet Respir Med. 2021;9(9):e93–e94. doi:10.1016/S2213-2600(21)00312-X
    OpenUrlCrossRef
  105. 105.
    Ghafouri-Fard S, Noroozi R, Vafaee R, et al. Effects of host genetic variations on response to, susceptibility and severity of respiratory infections. Biomed Pharmacother. 2020;128:110296. doi:10.1016/j.biopha.2020.110296
    OpenUrlCrossRef
  106. 106.
    Sainz J, Lupiáñez CB, Segura-Catena J, et al. Dectin-1 and DC-SIGN polymorphisms associated with invasive pulmonary Aspergillosis infection. PLoS One. 2012;7(2):e32273. doi:10.1371/journal.pone.0032273
    OpenUrlCrossRefPubMed
  107. 107.
    Avendaño-Tamayo E, Rúa A, Parra-Marín MV, et al. Evaluation of variants in IL6R, TLR3, and DC-SIGN genes associated with dengue in sampled Colombian population. Evaluación de variantes en los genes IL6R, TLR3 y DC-SIGN asociadas con dengue en una población colombiana muestreada. Biomedica. 2019;39(1):88–101. Published 2019 Mar 31. doi:10.7705/biomedica.v39i1.4029
    OpenUrlCrossRef
  108. 108.
    Vargas-Alarcón G, Posadas-Sánchez R, Ramírez-Bello J. Variability in genes related to SARS-CoV-2 entry into host cells (ACE2, TMPRSS2, TMPRSS11A, ELANE, and CTSL) and its potential use in association studies. Life Sci. 2020;260:118313. doi:10.1016/j.lfs.2020.118313
    OpenUrlCrossRef
  109. 109.
    Mortaz E, Tabarsi P, Varahram M, Folkerts G, Adcock IM. The Immune Response and Immunopathology of COVID-19. Front Immunol. 2020;11:2037. Published 2020 Aug 26. doi:10.3389/fimmu.2020.02037
    OpenUrlCrossRefPubMed
  110. 110.
    Solerte SB, Di Sabatino A, Galli M, Fiorina P. Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19. Acta Diabetol. 2020;57(7):779–783. doi:10.1007/s00592-020-01539-z
    OpenUrlCrossRef
  111. 111.
    Nelson CP, Sama IE, Codd V, et al. Genetic Associations With Plasma Angiotensin Converting Enzyme 2 Concentration: Potential Relevance to COVID-19 Risk. Circulation. 2020;142(11):1117–1119. doi:10.1161/CIRCULATIONAHA.120.049007
    OpenUrlCrossRefPubMed
  112. 112.
    Pedersen KB, Chhabra KH, Nguyen VK, Xia H, Lazartigues E. The transcription factor HNF1α induces expression of angiotensin-converting enzyme 2 (ACE2) in pancreatic islets from evolutionarily conserved promoter motifs. Biochim Biophys Acta. 2013;1829(11):1225–1235. doi:10.1016/j.bbagrm.2013.09.007
    OpenUrlCrossRefPubMed
  113. 113.
    Iyer GR, Samajder S, Zubeda S, et al. Infectivity and Progression of COVID-19 Based on Selected Host Candidate Gene Variants. Front Genet. 2020;11:861. Published 2020 Sep 4. doi:10.3389/fgene.2020.00861
    OpenUrlCrossRef
  114. 114.
    Prelli Bozzo C, Nchioua R, Volcic M, et al. IFITM proteins promote SARS-CoV-2 infection and are targets for virus inhibition in vitro. Nat Commun. 2021;12(1):4584. Published 2021 Jul 28. doi:10.1038/s41467-021-24817-y
    OpenUrlCrossRef
  115. 115.
    Zhang Y, Yang H, Li S, Li WD, Wang J, Wang Y. Association analysis framework of genetic and exposure risks for COVID-19 in middle-aged and elderly adults. Mech Ageing Dev. 2021;194:111433. doi:10.1016/j.mad.2021.111433
    OpenUrlCrossRef
  116. 116.
    Evans DM, Zhu G, Dy V, et al. Genome-wide association study identifies loci affecting blood copper, selenium and zinc. Hum Mol Genet. 2013;22(19):3998–4006. doi:10.1093/hmg/ddt239
    OpenUrlCrossRefPubMedWeb of Science
  117. 117.
    Spalinger MR, Hai R, Li J, et al. Identification of a Novel Susceptibility Marker for SARS-CoV-2 Infection in Human Subjects and Risk Mitigation with a Clinically Approved JAK Inhibitor in Human/Mouse Cells. Preprint. bioRxiv. 2020;2020.12.09.416586. Published 2020 Dec 9. doi:10.1101/2020.12.09.416586
    OpenUrlAbstract/FREE Full Text
  118. 118.
    Paniri A, Hosseini MM, Akhavan-Niaki H. First comprehensive computational analysis of functional consequences of TMPRSS2 SNPs in susceptibility to SARS-CoV-2 among different populations. J Biomol Struct Dyn. 2021;39(10):3576–3593. doi:10.1080/07391102.2020.1767690
    OpenUrlCrossRef
  119. 119.
    Karakas Celik S, Cakmak Genc G, Dursun A. A bioinformatic approach to investigating cytokine genes and their receptor variants in relation to COVID-19 progression. Int J Immunogenet. 2021;48(2):211–218. doi:10.1111/iji.12522
    OpenUrlCrossRef
  120. 120.
    Stairiker CJ, van Meurs M, Leon LG, et al. Heatr9 is an infection responsive gene that affects cytokine production in alveolar epithelial cells. PLoS One. 2020;15(7):e0236195. Published 2020 Jul 17. doi:10.1371/journal.pone.0236195
    OpenUrlCrossRef
  121. 121.
    Montoya MC, Sancho D, Bonello G, et al. Role of ICAM-3 in the initial interaction of T lymphocytes and APCs. Nat Immunol. 2002;3(2):159–168. doi:10.1038/ni753
    OpenUrlCrossRefPubMedWeb of Science
  122. 122.
    Hashemi SMA, Thijssen M, Hosseini SY, Tabarraei A, Pourkarim MR, Sarvari J. Human gene polymorphisms and their possible impact on the clinical outcome of SARS-CoV-2 infection. Arch Virol. 2021;166(8):2089–2108. doi:10.1007/s00705-021-05070-6
    OpenUrlCrossRef
  123. 123.
    Maiti AK. The African-American population with a low allele frequency of SNP rs1990760 (T allele) in IFIH1 predicts less IFN-beta expression and potential vulnerability to COVID-19 infection. Immunogenetics. 2020;72(6-7):387–391. doi:10.1007/s00251-020-01174-6
    OpenUrlCrossRef
  124. 124.
    Chong WP, Ip WK, Tso GH, et al. The interferon gamma gene polymorphism +874 A/T is associated with severe acute respiratory syndrome. BMC Infect Dis. 2006;6:82. Published 2006 May 4. doi:10.1186/1471-2334-6-82
    OpenUrlCrossRefPubMed
  125. 125.
    Farhan S, Nadeem M, Ahmed RS, Nadeem MT, Arshad MS, and Ullah A. Studying the impact of nutritional immunology underlying the modulation of immune responses by nutritional compounds–a review. Food and agricultural immunology. 2016; 27(2):205–229. doi: org/10.1080/09540105.2015.1079600
    OpenUrlCrossRef
  126. 126.
    Shane B, Pangilinan F, Mills JL, et al. The 677C→T variant of MTHFR is the major genetic modifier of biomarkers of folate status in a young, healthy Irish population. Am J Clin Nutr. 2018;108(6):1334–1341. doi:10.1093/ajcn/nqy209
    OpenUrlCrossRef
  127. 127.
    Schmiedel BJ, Singh D, Madrigal A, et al. Impact of Genetic Polymorphisms on Human Immune Cell Gene Expression. Cell. 2018;175(6):1701-1715.e16. doi:10.1016/j.cell.2018.10.022
    OpenUrlCrossRefPubMed
  128. 128.
    Smadja DM, Guerin CL, Chocron R, et al. Angiopoietin-2 as a marker of endothelial activation is a good predictor factor for intensive care unit admission of COVID-19 patients. Angiogenesis. 2020;23(4):611–620. doi:10.1007/s10456-020-09730-0
    OpenUrlCrossRefPubMed
  129. 129.
    Nagy B Jr, Fejes Z, Szentkereszty Z, et al. A dramatic rise in serum ACE2 activity in a critically ill COVID-19 patient. Int J Infect Dis. 2021;103:412–414. doi:10.1016/j.ijid.2020.11.184
    OpenUrlCrossRef
  130. 130.
    Hamet P, Pausova Z, Attaoua R, et al. SARS-CoV-2 Receptor ACE2 Gene Is Associated with Hypertension and Severity of COVID 19: Interaction with Sex, Obesity, and Smoking. Am J Hypertens. 2021;34(4):367–376. doi:10.1093/ajh/hpaa223
    OpenUrlCrossRef
  131. 131.
    Wooster L, Nicholson CJ, Sigurslid HH, Cardenas CLL, Malhotra R. Polymorphisms in the ACE2 locus associate with severity of COVID-19 infection.Preprint. medRxiv. 2020. doi: https://doi.org/10.1101/2020.06.18.20135152
  132. 132.
    Sun BB, Maranville JC, Peters JE, et al. Genomic atlas of the human plasma proteome. Nature. 2018;558(7708):73–79. doi:10.1038/s41586-018-0175-2
    OpenUrlCrossRefPubMed
  133. 133.
    Ali N. Elevated level of C-reactive protein may be an early marker to predict risk for severity of COVID-19. J Med Virol. 2020;92(11):2409–2411. doi:10.1002/jmv.26097
    OpenUrlCrossRef
  134. 134.
    Du Clos TW. Function of C-reactive protein. Ann Med. 2000;32(4):274–278. doi:10.3109/07853890009011772
    OpenUrlCrossRefPubMedWeb of Science
  135. 135.
    Sheu WH, Wang WC, Wu KD, et al. CRP-level-associated polymorphism rs1205 within the CRP gene is associated with 2-hour glucose level: The SAPPHIRe study. Sci Rep. 2017;7(1):7987. Published 2017 Aug 11. doi:10.1038/s41598-017-08696-2
    OpenUrlCrossRef
  136. 136.
    Chou SC, Ko HW, Lin YC. CRP/IL-6/IL-10 Single-Nucleotide Polymorphisms Correlate with the Susceptibility and Severity of Community-Acquired Pneumonia [published correction appears in Genet Test Mol Biomarkers. 2019 Jun;23(6):433]. Genet Test Mol Biomarkers. 2016;20(12):732–740. doi:10.1089/gtmb.2016.0156
    OpenUrlCrossRef
  137. 137.
    Chan KY, Ching JC, Xu MS, et al. Association of ICAM3 genetic variant with severe acute respiratory syndrome. J Infect Dis. 2007;196(2):271–280. doi:10.1086/518892
    OpenUrlCrossRefPubMedWeb of Science
  138. 138.
    Meyer NJ, Feng R, Li M, et al. IL1RN coding variant is associated with lower risk of acute respiratory distress syndrome and increased plasma IL-1 receptor antagonist. Am J Respir Crit Care Med. 2013;187(9):950–959. doi:10.1164/rccm.201208-1501OC
    OpenUrlCrossRefPubMed
  139. 139.
    Magro G. SARS-CoV-2 and COVID-19: Is interleukin-6 (IL-6) the ‘culprit lesion’ of ARDS onset? What is there besides Tocilizumab? SGP130Fc. Cytokine X. 2020;2(2):100029. doi:10.1016/j.cytox.2020.100029
    OpenUrlCrossRefPubMed
  140. 140.
    Nakanishi T, Pigazzini S, Degenhardt F, et al. Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality. Preprint. medRxiv. 2021;2021.03.07.21252875. Published 2021 Mar 12. doi:10.1101/2021.03.07.21252875
    OpenUrlAbstract/FREE Full Text
  141. 141.
    Ali RMM, Ghonimy MBI. Post-COVID-19 pneumonia lung fibrosis: a worrisome sequelae in surviving patients. The Egyptian Journal of Radiology and Nuclear Medicine. 2021;52(1):101. doi:10.1186/s43055-021-00484-3
    OpenUrlCrossRef
  142. 142.
    Seibold MA, Wise AL, Speer MC, et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med. 2011;364(16):1503–1512. doi:10.1056/NEJMoa1013660
    OpenUrlCrossRefPubMedWeb of Science
  143. 143.
    Andolfo I, Russo R, Lasorsa VA, et al. Common variants at 21q22.3 locus influence MX1 and TMPRSS2 gene expression and susceptibility to severe COVID-19. iScience. 2021;24(4):102322. doi:10.1016/j.isci.2021.102322
    OpenUrlCrossRef
  144. 144.
    Hu J, Li C, Wang S, Li T, Zhang H. Genetic variants are identified to increase risk of COVID-19 related mortality from UK Biobank data. Hum Genomics. 2021;15(1):10. Published 2021 Feb 3. doi:10.1186/s40246-021-00306-7
    OpenUrlCrossRef
  145. 145.
    Gómez J, Albaiceta GM, García-Clemente M, et al. Angiotensin-converting enzymes (ACE, ACE2) gene variants and COVID-19 outcome. Gene. 2020;762:145102. doi:10.1016/j.gene.2020.145102
    OpenUrlCrossRefPubMed
  146. 146.
    Liu C, Pei J, Lai Y, et al. Association of ACE2 variant rs4646188 with the risks of atrial fibrillation and cardioembolic stroke in Uygur patients with type 2 diabetes. BMC Cardiovasc Disord. 2021;21(1):103. Published 2021 Feb 18. doi:10.1186/s12872-021-01915-9
    OpenUrlCrossRef
  147. 147.
    Pan Y, Wang T, Li Y, et al. Association of ACE2 polymorphisms with susceptibility to essential hypertension and dyslipidemia in Xinjiang, China. Lipids Health Dis. 2018;17(1):241. Published 2018 Oct 20. doi:10.1186/s12944-018-0890-6
    OpenUrlCrossRefPubMed
  148. 148.
    Luo Y, Liu C, Guan T, et al. Association of ACE2 genetic polymorphisms with hypertension-related target organ damages in south Xinjiang [published correction appears in Hypertens Res. 2019 Jan 23;:]. Hypertens Res. 2019;42(5):681–689. doi:10.1038/s41440-018-0166-6
    OpenUrlCrossRefPubMed
  149. 149.
    Kochetova OV, Avzaletdinova DS, Morugova TV, Mustafina OE. Chemokine gene polymorphisms association with increased risk of type 2 diabetes mellitus in Tatar ethnic group, Russia. Mol Biol Rep. 2019;46(1):887–896. doi:10.1007/s11033-018-4544-6
    OpenUrlCrossRef
  150. 150.
    polymorphism with tuberculosis susceptibility: A meta-analysis. Innate Immun. 2020;26(5):358–363. doi:10.1177/1753425919891662rs2107538 Sheng YF, Qi Q. Association of chemotactic chemokine ligand 5
    OpenUrlCrossRef
  151. 151.
    Lu S, Wang Y, Wang Y, et al. The IL-6 rs1800795 and rs1800796 polymorphisms are associated with coronary artery disease risk. J Cell Mol Med. 2020;24(11):6191–6207. doi:10.1111/jcmm.15246
    OpenUrlCrossRef
  152. 152.
    Oosterveer DM, Versmissen J, Defesche JC, et al. Low-density lipoprotein receptor mutations generate synthetic genome-wide associations. Eur J Hum Genet. 2013;21(5):563–566. doi:10.1038/ejhg.2012.207
    OpenUrlCrossRef
  153. 153.↵
  154. 154.↵
  155. 155.↵
Back to top
Posted December 15, 2021.
Download PDF
Data/Code
Email
COVID-19 and Indian population: a comparative genetic analysis
Saurabh Patil, Sandhya Kiran Pemmasani, Neelima Chitturi, Ishita Bhatnagar, Anuradha Acharya, Lingareddy Venkata Subash
medRxiv 2021.12.15.21267816; doi: https://doi.org/10.1101/2021.12.15.21267816
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area